Search
for
Sort by
Research 151–180 of 321
- Combined C3b and Factor B Autoantibodies and MPGN Type II
- Frontal fibrosing alopecia: An update on the hypothesis of pathogenesis and treatment
- Tufted hair folliculitis developing in a recalcitrant lesion of pemphigus vulgaris
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
- Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives
- Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report
- Azathioprine-induced Agranulocytosis and Severe Alopecia After Kidney Transplantation Associated With a NUDT15 Polymorphism: A Case Report
- The financial burden of scalp cooling therapy: A nonprofit organization data analysis
- Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg
- USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
- Atypical bilateral hyperpigmented macules on the lower legs possibly due to cyclophosphamide.
- Primary vitreoretinal lymphoma masquerading as refractory uveitis—just go with the flow
- Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome
- Modern and Promising Strategies for Treatment of Alopecia in the United States: Clinical and Pharmacological, Marketing, Regulatory, SWOT Analysis
- OA08 Ocrelizumab in pregnancy in a patient with juvenile onset systemic lupus erythematosus
- P13 DMARD preconception counselling and reinforcement should be a norm in all rheumatology clinics
- 50832 Confetti variant of Alopecia Areata: A Single Center Retrospective Study to Describe a Novel Entity
- LB1011 Cost and access changes with TNFa inhibitor biosimilars entering the market
- Effective treatment of alopecia universalis with oral tofacitinib: A case report
- Lymphoma Specialists Lament the Discontinuation of Underprescribed Bexxar
- Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Vaccines, adjuvants and autoimmunity
- The use of cyclosporine in dermatology: Part I
- Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review
- Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Immunosuppressive treatment for proliferative lupus nephritis